HALO Stock Risk & Deep Value Analysis

Halozyme Therapeutics Inc

Healthcare • Biotechnology

DVR Score

7.4

out of 10

Solid Pick

What You Need to Know About HALO Stock

We analyzed Halozyme Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran HALO through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.

Updated Mar 8, 2026•Run Fresh Analysis →

How Risky Is HALO Stock?

Overall Risk

Moderate

Financial Risk

Low

Market Risk

Low

Competitive Risk

Medium

Execution Risk

Low

Regulatory Risk

Medium

What Are the Red Flags for HALO?

⚠
Patent challenges to ENHANZE technology
⚠
Clinical trial failures or regulatory setbacks for key partner products
⚠
Development of superior alternative drug delivery technologies by competitors

Unlock HALO Red Flags & Risk Warnings

Create a free account to see the full analysis

What Does Halozyme Therapeutics Inc (HALO) Do?

Market Cap

$7.63B

Sector

Healthcare

Industry

Biotechnology

Employees

350

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Visit Halozyme Therapeutics Inc Website

Is HALO Stock Undervalued?

Halozyme continues to impress with its robust ENHANZE technology, solidifying its competitive moat and driving a high-margin royalty business from a diversified portfolio of pharmaceutical partners. The company's strategic vision, strong financial health, and proven leadership provide a foundation for consistent growth. The recent decrease in market capitalization from $9.34B to $7.95B slightly improves the relative path to achieving a 10x return, making the target of $79.5B incrementally less challenging than previously. However, the royalty-centric model, while highly scalable and profitable, inherently leans towards incremental rather than the exponential growth typically required for a 10x return within 3-5 years from its current scale. No other material changes warrant a significant score adjustment, thus a slight upward revision reflects the marginally improved potential for the 10x target.

Unlock the full AI analysis for HALO

Get the complete DVR score, risk analysis, and more

Is HALO Financially Healthy?

P/E Ratio

14.92

Does HALO Have a Competitive Moat?

Moat Rating

🛡️ Narrow

Moat Trend

Stable

Moat Sources

2 Identified

Intangible Assets/IPSwitching Costs

Halozyme's moat is durable due to strong patent protection for its rHuPH20 enzyme and the high switching costs associated with integrating a drug delivery technology into a partner's late-stage clinical development and regulatory filings. The extensive clinical data and regulatory precedent also provide a significant barrier to entry.

Moat Erosion Risks

•Expiration of key ENHANZE patents
•Development of highly superior, competing subcutaneous drug delivery platforms
•Regulatory shifts impacting drug formulation changes

HALO Competitive Moat Analysis

What Could Drive HALO Stock Higher?

Near-Term (0-6 months)

•Q1 2026 Earnings Report (Estimated early May 2026)
•Additional global approvals/launches of argenx's Vyvgart Hytrulo
•Updates on existing partner pipelines utilizing ENHANZE

Medium-Term (6-18 months)

•Potential new ENHANZE partnership announcements
•Expansion of existing partner products into new indications or geographies
•Progress on next-generation ENHANZE platform enhancements

Long-Term (18+ months)

•Continued broad industry adoption of subcutaneous drug delivery via ENHANZE
•Halozyme becoming an attractive acquisition target for its IP and royalty stream
•Growth in partner product sales translating to increasing royalty revenues

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for HALO?

✓
Acceleration in new partnership announcements or expansion of existing deals
✓
Strong growth in underlying sales of partner products utilizing ENHANZE
✓
Positive outcomes from any patent litigation or regulatory updates related to ENHANZE

Bull Case Analysis

See what could go right with Premium

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

Analyze Any Stock →View Top 100 Deep Value Stocks →

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for HALO (Halozyme Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.